Skip to main content
University of California San Francisco
About UCSF
Search UCSF
UCSF Medical Center
Radiology
Search
About
People
Opportunity and Outreach
Wellbeing and Professional Climate
Make a Gift
Contact Us
Patient Care
For Health Professionals
For Patients
Services Offered
Clinical Divisions
Patient Safety
Education
Diagnostic Radiology Residency
Integrated IR Residency
Independent IR Residency
NucMed Residency & Fellowship
Fellowships
T32 Program
Medical Student Education
Master of Science in Biomedical Imaging (MSBI)
Continuing Medical Education
The Margulis Society for Alumni
Distinguished Lecture Series
Research
Research Directory
Imaging Research Symposium
Research Conference
UCSF Radiology at RSNA
Core Services
Academic Affairs
Academic Recruitment
Academic Advancement
Development & Courses
Faculty Mentoring
Faculty Thrive Guide
Celebrating Faculty & Alumni
Department Committees
FAQs
Locations
News
Events
Honors and Awards
Department Publications
Breadcrumb
Home
/
About
/
People
/
Nola Hylton, PhD
/
Publications
Nola Hylton, PhD's Publications
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer.
Novel Postneoadjuvant Prognostic Breast Cancer Staging System.
18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.
Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge.
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study.
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study.
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
Deep Learning to Simulate Contrast-enhanced Breast MRI of Invasive Breast Cancer.
Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy.
Deep Learning to Simulate Contrast-enhanced Breast MRI of Invasive Breast Cancer.
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy.
Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer.
Expert tumor annotations and radiomics for locally advanced breast cancer in DCE-MRI for ACRIN 6657/I-SPY1.
Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial.
Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial.
Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response.
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
18F-FDG PET/CT Predicts Response to HER2-directed Neoadjuvant Therapy.
Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
Mask-Guided Convolutional Neural Network for Breast Tumor Prognostic Outcome Prediction on 3D DCE-MR Images.
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
The Way of the Future: Personalizing Treatment Plans Through Technology.
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.
Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
Denoising and Multiple Tissue Compartment Visualization of Multi-b-Valued Breast Diffusion MRI.
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Evaluation of primary breast cancers using dedicated breast PET and whole-body PET.
Factors Affecting Image Quality and Lesion Evaluability in Breast Diffusion-weighted MRI: Observations from the ECOG-ACRIN Cancer Research Group Multisite Trial (A6702).
Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial.
Mean Apparent Diffusion Coefficient Is a Sufficient Conventional Diffusion-weighted MRI Metric to Improve Breast MRI Diagnostic Performance: Results from the ECOG-ACRIN Cancer Research Group A6702 Diffusion Imaging Trial.
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
Repeatability and Reproducibility of ADC Histogram Metrics from the ACRIN 6698 Breast Cancer Therapy Response Trial.
Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study.
Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer.
Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Complete Breast MRI Response to Neoadjuvant Chemotherapy and Prediction of Pathologic Complete Response.
Diffusion-weighted MRI in Multicenter Trials of Breast Cancer.
Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration.
Pubertal timing and breast density in young women: a prospective cohort study.
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis.
Intake of dietary carbohydrates in early adulthood and adolescence and breast density among young women.
MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
Residual Disease after Neoadjuvant Therapy for Breast Cancer: Can MRI Help?
Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.
Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment.
Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study.
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
Effect of Background Parenchymal Enhancement on Breast MR Imaging Interpretive Performance in Community-based Practices.
Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.
Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network.
Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial
Adaptive Randomization of Neratinib in Early Breast Cancer.
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Computational Challenges and Collaborative Projects in the NCI Quantitative Imaging Network.
Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.
Design of a breast phantom for quantitative MRI.
Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.
Early Life Body Fatness, Serum Anti-Müllerian Hormone, and Breast Density in Young Adult Women.
Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.
MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.
Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.
Quantitative Imaging in Cancer Clinical Trials.
Variability and bias assessment in breast ADC measurement across multiple systems.
Adolescent endogenous sex hormones and breast density in early adulthood.
Body fatness during childhood and adolescence and breast density in young women: a prospective analysis.
Extra-mammary findings on breast MRI: a pictorial review.
Gradient nonlinearity correction to improve apparent diffusion coefficient accuracy and standardization in the american college of radiology imaging network 6698 breast cancer trial.
How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.
Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy.
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
Errors in Quantitative Image Analysis due to Platform-Dependent Image Scaling.
Image registration for quantitative parametric response mapping of cancer treatment response.
Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis.
Lesion morphology on breast MRI affects targeted ultrasound correlation rate.
Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform.
Repeatability of quantitative MRI measurements in normal breast tissue.
Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers.
Agreement of mammographic measures of volumetric breast density to MRI.
Breast magnetic resonance imaging for monitoring response to therapy.
Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Features of occult invasion in biopsy-proven DCIS at breast MRI.
High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: a pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging.
High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response.
High-resolution diffusion-weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3T.
Intraductal therapy of ductal carcinoma in situ: a presurgery study.
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
Menstrual and reproductive characteristics and breast density in young women.
MR imaging for the prediction of breast cancer response to neoadjuvant chemotherapy.
MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy.
Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.
Recognizing artifacts and optimizing breast MRI at 1.5 and 3 T.
Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging.
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.
Height, adiposity and body fat distribution and breast density in young women.
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
Can signal enhancement ratio (SER) reduce the number of recommended biopsies without affecting cancer yield in occult MRI-detected lesions?
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Diffusion-weighted MRI: influence of intravoxel fat signal and breast density on breast tumor conspicuity and apparent diffusion coefficient measurements.
High-resolution diffusion-weighted magnetic resonance imaging in patients with locally advanced breast cancer.
MRI appearance of tumor recurrence in myocutaneous flap reconstruction after mastectomy.
MRI in breast cancer therapy monitoring.
Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.
Quantification of background enhancement in breast magnetic resonance imaging.
Quantitative tissue oxygen measurement in multiple organs using 19F MRI in a rat model.
The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ.
Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI.
Adolescent diet and subsequent serum hormones, breast density, and bone mineral density in young women: results of the Dietary Intervention Study in Children follow-up study.
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
Role of breast MR imaging in neoadjuvant chemotherapy.
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
Can diffuse optical spectroscopic tomography be used to characterize breast lesions and their response to treatment?
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
Magnetic resonance imaging for secondary assessment of breast density in a high-risk cohort.
MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model.
Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy.
Ductal carcinoma in situ: state of the science and roadmap to advance the field.
Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Characterization of breast lesions using the 3D FIESTA sequence and contrast-enhanced magnetic resonance imaging.
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging.
Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ.
Diagnostic architectural and dynamic features at breast MR imaging: multicenter study.
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.
Magnetic resonance imaging captures the biology of ductal carcinoma in situ.
MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy.
Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial.
Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study.
Four-phase single-capillary stepwise model for kinetics in arterial spin labeling MRI.
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
Magnetic resonance imaging of the breast: opportunities to improve breast cancer management.
MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883.
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation.
Screening women at high risk for breast cancer with mammography and magnetic resonance imaging.
Magnetic resonance imaging of the breast prior to biopsy.
Quantification of breast tissue index from MR data using fuzzy clustering.
Evaluation of gadobenate dimeglumine for contrast-enhanced MRI of the breast.
Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity.
Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.
Magnetic resonance imaging for primary breast cancer management: current role and new applications.
Challenges to interpretation of breast MRI.
Development, standardization, and testing of a lexicon for reporting contrast-enhanced breast magnetic resonance imaging studies.
Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI.
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.
Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging.
Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability.
Integration of breast imaging into cancer management.
MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging.
Suspension of breast-feeding following gadopentetate dimeglumine administration.
Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.
Dedicated Breast MRI Systems Working Group report.
Semi-automated analysis for MRI of breast tumors.
Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.
Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging.
Technical aspects of breast magnetic resonance imaging.
Evaluation of the effects of intravascular MR contrast media (gadolinium dendrimer) on 3D time of flight magnetic resonance angiography of the body.
Imaging techniques for breast MR imaging.
Impact of section doubling on MR angiography.
Characterization of arterial blood flow using magnetic resonance imaging techniques.
MRA: how it's done and what it shows.
Oblique reformatting of multislice magnetic resonance images for improved visualization of coronary arteries.
Echo-planar pediatric imager.
Partial flip angle MR imaging.
The value of relaxation times and density measurements in clinical MRI.
Information processing in magnetic resonance imaging.
Optimal visualization of the cerebrospinal fluid on MRI.
Multiple spin-echo magnetic resonance imaging.
Variable magnetic resonance imaging parameters: effect on detection and characterization of lesions.
Analytical tools for magnetic resonance imaging.
NMR in experimental cerebral edema: value of T1 and T2 calculations.
Signal to noise in derived NMR images.
